Should I buy or sell Seres Therapeutics stock right now?

3 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Seres Therapeutics in the last twelve months. There are currently 1 hold rating and 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" MCRB shares. View MCRB analyst ratings or view top-rated stocks .

What is Seres Therapeutics' stock price target for 2024?

3 brokerages have issued twelve-month target prices for Seres Therapeutics' stock. Their MCRB share price targets range from $5.00 to $8.00. On average, they anticipate the company's stock price to reach $6.67 in the next year. This suggests a possible upside of 944.9% from the stock's current price. View analysts price targets for MCRB or view top-rated stocks among Wall Street analysts .

How have MCRB shares performed in 2024?

Seres Therapeutics' stock was trading at $1.40 at the beginning of 2024. Since then, MCRB stock has decreased by 54.4% and is now trading at $0.6380. View the best growth stocks for 2024 here .

When is Seres Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, May 14th 2024. View our MCRB earnings forecast .

How were Seres Therapeutics' earnings last quarter?

Seres Therapeutics, Inc. (NASDAQ:MCRB) posted its earnings results on Tuesday, March, 5th. The biotechnology company reported ($0.32) earnings per share for the quarter, topping analysts' consensus estimates of ($0.40) by $0.08. The biotechnology company had revenue of $0.06 million for the quarter, compared to analyst estimates of $0.50 million.

What other stocks do shareholders of Seres Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Seres Therapeutics investors own include OPKO Health (OPK) , TherapeuticsMD (TXMD) , Juno Therapeutics (JUNO) , NVIDIA (NVDA) , Walt Disney (DIS) , Alibaba Group (BABA) , Novavax (NVAX) , Advanced Micro Devices (AMD) , Dynavax Technologies (DVAX) and Gilead Sciences (GILD) .

When did Seres Therapeutics IPO?

Seres Therapeutics (MCRB) raised $101 million in an IPO on Friday, June 26th 2015. The company issued 6,300,000 shares at $15.00-$17.00 per share. Goldman Sachs and BofA Merrill Lynch acted as the underwriters for the IPO and Leerink Partners and Canaccord Genuity were co-managers.

How do I buy shares of Seres Therapeutics?

Shares of MCRB stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

NASDAQ:MCRB

Seres Therapeutics (MCRB) Stock Price, News & Analysis

→ AI “wealth window” is closing soon! (From Paradigm Press) (Ad)

Free MCRB Stock Alerts

$0.64

+0.02 (+3.79%)

(As of 01:50 PM ET)

Compare

Today's Range: $0.61
▼
$0.66
50-Day Range: $0.62
▼
$1.23
52-Week Range: $0.61
▼
$6.87

Volume: 3.17 million shs
Average Volume: 4.59 million shs
Market Capitalization: $96.84 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $6.67

Get Seres Therapeutics alerts:

Seres Therapeutics MarketRank™ Stock Analysis

Analyst Rating: Moderate Buy
2.67 Rating Score
Upside/Downside: 944.9% Upside
$6.67 Price Target
Short Interest: Bearish
12.45% of Shares Sold Short
Dividend Strength: N/A
Sustainability: -1.14
Upright™ Environmental Score
News Sentiment: 0.82
Based on 2 Articles This Week
Insider Trading: Selling Shares
$20,371 Sold Last Quarter
Proj. Earnings Growth: Growing
From ($1.15) to ($0.84) Per Share

Overall MarketRank^™

New Rank-Based ScoringMarketRank^™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

3.67 out of 5 stars

Medical Sector

228th out of 930 stocks

Pharmaceutical Preparations Industry

94th out of 430 stocks

3.3

Analyst's Opinion

Consensus Rating
Seres Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.67, and is based on 2 buy ratings, 1 hold rating, and no sell ratings.
Amount of Analyst Coverage
Seres Therapeutics has only been the subject of 2 research reports in the past 90 days.

1.0

Short Interest

Percentage of Shares Shorted
12.45% of the outstanding shares of Seres Therapeutics have been sold short.
Short Interest Ratio / Days to Cover
Seres Therapeutics has a short interest ratio ("days to cover") of 4.
Change versus previous month
Short interest in Seres Therapeutics has recently increased by 2.17%, indicating that investor sentiment is decreasing.

0.0

Dividend Strength

Dividend Yield
Seres Therapeutics does not currently pay a dividend.
Dividend Growth
Seres Therapeutics does not have a long track record of dividend growth.

4.6

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
Seres Therapeutics has received a 71.59% net impact score from Upright. The largest positive contribution comes from its "Creating knowledge" impact, which is false driven by its "Clinical research services for infectious diseases", "Clinical research services for physiological diseases ", and "Preclinical research services for physical health" products. See details.
Environmental Sustainability
The Environmental Impact score for Seres Therapeutics is -1.14.

2.7

News and Social Media Coverage

News Sentiment
Seres Therapeutics has a news sentiment score of 0.82. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.66 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 2 news articles for Seres Therapeutics this week, compared to 2 articles on an average week.
Search Interest
Only 21 people have searched for MCRB on MarketBeat in the last 30 days. This is a decrease of -36% compared to the previous 30 days.
MarketBeat Follows
11 people have added Seres Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 22% compared to the previous 30 days.

1.7

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Seres Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $20,371.00 in company stock.
Percentage Held by Insiders
Only 5.10% of the stock of Seres Therapeutics is held by insiders.
Percentage Held by Institutions
59.34% of the stock of Seres Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.6

Earnings and Valuation

Earnings Growth
Earnings for Seres Therapeutics are expected to grow in the coming year, from ($1.15) to ($0.84) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Seres Therapeutics is -0.71, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Seres Therapeutics is -0.71, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

See Top Rated MarketRank™ Stocks Here

Ad Paradigm Press

AI “wealth window” is closing soon!

Today, I’m making my boldest prediction ever. Next-generation AI technology will create the first $100 TRILLION industry.

I put together this personal video [HERE]…

About Seres Therapeutics Stock (NASDAQ:MCRB)

Seres Therapeutics, Inc., a microbiome therapeutics company, develop microbiome therapeutics to treat the modulation of the colonic microbiome. It develops a novel class of biological drugs that are designed to treat by modulating the microbiome to restore health by repairing the function of a disrupted microbiome to a non-disease state. The company's lead product candidate is VOWST, an oral microbiome therapeutic that has completed Phase III clinical trial for the treatment of recurrent Clostridioides difficile infection. Its product pipeline also includes SER-155, an investigational oral fermented microbiome therapeutic which is in Phase 1b clinical trials for the treatment of gastrointestinal infections, bacteremia, and graft versus host disease in immunocompromised patients including patients receiving allogeneic hematopoietic stem cell transplantation. In addition, the company engages in the development of SER-287 which is in Phase 2b and SER-301 that is in Phase 1b to treat ulcerative colitis. Further, it has license Agreement with NHSc Rx License GmbH for the therapeutic products based on the microbiome technology, which includes VOWST product candidate, which is developed for the treatment of CDI and recurrent CDI; and collaboration license agreement with Société des Produits Nestlé S.A. (Nestlé) for the development and commercialization of certain product candidates for the treatment and management of CDI and inflammatory bowel disease including UC and Crohn's disease. The company was formerly known as Seres Health, Inc. and changed its name to Seres Therapeutics, Inc. in May 2015. Seres Therapeutics, Inc. was incorporated in 2010 and is headquartered in Cambridge, Massachusetts.

MCRB Stock Price History

30 days | 90 days | 365 days | Advanced Chart

MCRB Stock News Headlines

April 16, 2024 | americanbankingnews.com

Seres Therapeutics (NASDAQ:MCRB) Stock Price Passes Below 50-Day Moving Average of $0.91

April 9, 2024 | businesswire.com

Seres Therapeutics Announces Completion of Patient Enrollment for SER-155 Phase 1B Cohort 2 Clinical Trial in Allogenic HSCT

April 16, 2024 | Paradigm Press (Ad)

AI “wealth window” is closing soon!

Today, I’m making my boldest prediction ever. Next-generation AI technology will create the first $100 TRILLION industry.

March 28, 2024 | finance.yahoo.com

Increases to Seres Therapeutics, Inc.'s (NASDAQ:MCRB) CEO Compensation Might Cool off for now

March 11, 2024 | finance.yahoo.com

MCRB Apr 2024 1.000 put

March 7, 2024 | finance.yahoo.com

Seres Therapeutics, Inc. (NASDAQ:MCRB) Q4 2023 Earnings Call Transcript

March 6, 2024 | realmoney.thestreet.com

Seres Therapeutics price target lowered by $4 at Oppenheimer, here's why

March 6, 2024 | markets.businessinsider.com

Seres Therapeutics (MCRB) Gets a Buy from TD Cowen

April 16, 2024 | Paradigm Press (Ad)

AI “wealth window” is closing soon!

Today, I’m making my boldest prediction ever. Next-generation AI technology will create the first $100 TRILLION industry.

March 6, 2024 | finance.yahoo.com

Q4 2023 Seres Therapeutics Inc Earnings Call

March 5, 2024 | investorplace.com

MCRB Stock Earnings: Seres Therapeutics Beats EPS for Q4 2023

March 5, 2024 | investorplace.com

Gold Price Alert: Gold Spot Prices Just Hit a Record High Today

March 5, 2024 | msn.com

Seres Therapeutics GAAP EPS of -$0.89 beats by $0.10, revenue of $126.33M beats by $0.23M

March 5, 2024 | finance.yahoo.com

Seres Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Updates

March 5, 2024 | finance.yahoo.com

Seres Therapeutics Inc (MCRB) Reports Encouraging Sales Growth and Strategic Cost Savings in 2023

March 4, 2024 | benzinga.com

Seres Therapeutics's Earnings: A Preview

March 2, 2024 | morningstar.com

Seres Therapeutics Inc MCRB

February 28, 2024 | businesswire.com

Seres Therapeutics to Host Fourth Quarter 2023 Financial Results and Operational Progress Conference Call and Webcast on March 5, 2024

February 27, 2024 | finance.yahoo.com

Seres Therapeutics to Participate in Cowen 44th Annual Healthcare Conference

February 27, 2024 | businesswire.com

Seres Therapeutics to Participate in Cowen 44th Annual Healthcare Conference

February 26, 2024 | markets.businessinsider.com

Seres Therapeutics Appoints Marella Thorell As New CFO Following Retirement Of David Arkowitz

February 26, 2024 | finance.yahoo.com

Seres Therapeutics Announces the Appointment of Marella Thorell as Chief Financial Officer and the Retirement of David Arkowitz

February 26, 2024 | businesswire.com

Seres Therapeutics Announces the Appointment of Marella Thorell as Chief Financial Officer and the Retirement of David Arkowitz

February 22, 2024 | benzinga.com

Seres Therapeutics Stock (NASDAQ:MCRB), Short Interest Report

February 18, 2024 | msn.com

New Seres 3 arrives in the UK priced from £29,995

February 18, 2024 | msn.com

Meet the UK's cheapest new electric SUV: the new Seres 3, yours for just under £30k

February 7, 2024 | markets.businessinsider.com

Sell Rating on Seres Therapeutics Amid Underperforming Sales and Financial Challenges

See More Headlines

Receive MCRB Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Seres Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 3/05/2024
Today: 4/16/2024
Next Earnings (Estimated): 5/14/2024
Fiscal Year End: 12/31/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: Medical
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Current Symbol: NASDAQ:MCRB
CUSIP: N/A
CIK: 1609809
Web: www.serestherapeutics.com
Phone: (617) 945-9626
Fax: N/A
Employees: 233
Year Founded: N/A

Price Target and Rating

Average Stock Price Target: $6.67
High Stock Price Target: $8.00
Low Stock Price Target: $5.00
Potential Upside/Downside: +978.9%
Consensus Rating: Moderate Buy
Rating Score (0-4): 2.67
Research Coverage: 3 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($0.90)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-113,720,000.00
Net Margins: N/A
Pretax Margin: -90.03%
Return on Equity: N/A
Return on Assets: -32.43%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 1.78
Quick Ratio: 1.48

Sales & Book Value

Annual Sales: $126.32 million
Price / Sales: 0.74
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: ($0.35) per share
Price / Book: -1.77

Miscellaneous

Outstanding Shares: 151,010,000
Free Float: 143,308,000
Market Cap: $93.31 million
Optionable: Optionable
Beta: 2.24

10 Best Stocks to Own in 2024

Click the link below and we'll send you MarketBeat's list of the 10 best stocks to own in 2024 and why they should be in your portfolio.

Get This Free Report

Key Executives

Mr. Eric D. Shaff M.B.A. (Age 48)
President, CEO & Director
Comp: $1.02M
Dr. Lisa von Moltke M.D. (Age 65)
Executive VP & Chief Medical Officer
Comp: $725.15k
Dr. Teresa L. Young Ph.D. (Age 57)
R.Ph., Executive VP and Chief Commercial & Strategy Officer
Comp: $606.33k

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

MCRB Stock Analysis - Frequently Asked Questions

Should I buy or sell Seres Therapeutics stock right now?: 3 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Seres Therapeutics in the last twelve months. There are currently 1 hold rating and 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" MCRB shares.
View MCRB analyst ratings or view top-rated stocks.
What is Seres Therapeutics' stock price target for 2024?: 3 brokerages have issued twelve-month target prices for Seres Therapeutics' stock. Their MCRB share price targets range from $5.00 to $8.00. On average, they anticipate the company's stock price to reach $6.67 in the next year. This suggests a possible upside of 944.9% from the stock's current price.
View analysts price targets for MCRB or view top-rated stocks among Wall Street analysts.
How have MCRB shares performed in 2024?: Seres Therapeutics' stock was trading at $1.40 at the beginning of 2024. Since then, MCRB stock has decreased by 54.4% and is now trading at $0.6380.
View the best growth stocks for 2024 here.
When is Seres Therapeutics' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Tuesday, May 14th 2024.
View our MCRB earnings forecast.

How were Seres Therapeutics' earnings last quarter?: Seres Therapeutics, Inc. (NASDAQ:MCRB) posted its earnings results on Tuesday, March, 5th. The biotechnology company reported ($0.32) earnings per share for the quarter, topping analysts' consensus estimates of ($0.40) by $0.08. The biotechnology company had revenue of $0.06 million for the quarter, compared to analyst estimates of $0.50 million.
What other stocks do shareholders of Seres Therapeutics own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Seres Therapeutics investors own include OPKO Health (OPK), TherapeuticsMD (TXMD), Juno Therapeutics (JUNO), NVIDIA (NVDA), Walt Disney (DIS), Alibaba Group (BABA), Novavax (NVAX), Advanced Micro Devices (AMD), Dynavax Technologies (DVAX) and Gilead Sciences (GILD).
When did Seres Therapeutics IPO?: Seres Therapeutics (MCRB) raised $101 million in an IPO on Friday, June 26th 2015. The company issued 6,300,000 shares at $15.00-$17.00 per share. Goldman Sachs and BofA Merrill Lynch acted as the underwriters for the IPO and Leerink Partners and Canaccord Genuity were co-managers.
How do I buy shares of Seres Therapeutics?: Shares of MCRB stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:MCRB) was last updated on 4/16/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

Seres Therapeutics (MCRB) Stock Price, News & Analysis

Seres Therapeutics MarketRank™ Stock Analysis

Overall MarketRank™

Analyst's Opinion

Short Interest

Percentage of Shares Shorted

Short Interest Ratio / Days to Cover

Change versus previous month

Dividend Strength

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score

Environmental Sustainability

News and Social Media Coverage

News Sentiment

News Coverage This Week

Search Interest

MarketBeat Follows

Company Ownership

Earnings and Valuation

About Seres Therapeutics Stock (NASDAQ:MCRB)

MCRB Stock Price History

MCRB Stock News Headlines

Company Calendar

Industry, Sector and Symbol

Price Target and Rating

Profitability

Debt

Sales & Book Value

Miscellaneous

Key Executives

Key Competitors

Insiders & Institutions

MCRB Stock Analysis - Frequently Asked Questions

Overall MarketRank^™